The pharmacokinetic and thrombolytic properties were determined of two recombinant single-chain chimeric plasminogen activators (PA) consisting of u-PA-33k, a low-molecular weight derivative of single-chain urokinase-type PA (scu-PA) comprising amino acids Ala132 through Leu411, and of either a single-chain variable region fragment (Fv) derived from the fibrin fragment D-dimer-specific monoclon...

background : immunogenicity of streptokinase (stk), as a thrombolytic drug, have limited its clinical use. elimination of the amino acid residues that are responsible for immunogenicity while don’t affect the bioactivity of stk is worthy. recently, we modified the stk through elimination of 42 amino acids from its’ c-terminal and assessed its bioactivity in vitro . objective : in this study, bi...

Background: Thrombolytic therapy used in patients with acute myocardial infarction may increase the risk of stroke. Scant information is available from community-based studies. Summary of Report: Among 5,635 consecutive patients admitted with acute myocardial infarction to hospitals in Seattle and surrounding suburban King County, Washington, 116 (2.1%) experienced strokes during hospitalizatio...

This research was carried out to investigate the thrombolytic effects of the methanolic extracts of five Bangladeshi plants. Phytochemical metabolites of those plants have been identified to elucidate whether the plant-derived metabolites are linked with the thrombolytic effects. Potential computer aided models were adopted in this study to find out a structure-function correlation between the ...

uring the 1980s, thrombolytic therapy became the initial reatment for patients with acute myocardial infarction AMI). Toward the end of the decade, primary percutaneus coronary intervention (PCI) was shown to be effective 1,2), and a recent analysis of 23 randomized trials demontrated improved rates of reinfarction, stroke, and death ompared with thrombolytic therapy (3). However, because f lim...

OBJECTIVES We sought to assess the efficacy and safety of thrombolytic therapy in patients with an acute pulmonary embolism (PE). BACKGROUND Thrombolytic therapy is approved for the treatment of acute PE; however, the safety and efficacy of this therapy remain debated. METHODS A meta-analysis of randomized, controlled trials comparing thrombolytic agents with intravenous heparin in patients wit...

BACKGROUND The value of thrombolytic therapy in unstable angina is unclear. METHODS AND RESULTS To study this problem, 159 patients were studied in a double-blind, placebo-controlled multicenter trial. Patients without a previous myocardial infarction, with a typical history of unstable angina, and ECG abnormalities indicative of ischemia were included. After baseline angiography, study medic...

BACKGROUND Thrombolytic therapy used in patients with acute myocardial infarction may increase the risk of stroke. Scant information is available from community-based studies. SUMMARY OF REPORT Among 5,635 consecutive patients admitted with acute myocardial infarction to hospitals in Seattle and surrounding suburban King County, Washington, 116 (2.1%) experienced strokes during hospitalizatio...

Comparison of the Success Rate Treatment with Primary Percutaneous Coronary Intervention PCI versus Thrombolytic in Patients ST-Elevation Myocardial Infarction Local Hospitals Iran